GEH121224 (18F)

N/A

Report date: 2026/03/31 20:00:21

NME

Base Information

Drug NameGEH121224 (18F)

Drug Alias Name[18F]GEH121224GEH121224 (18F)

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radioactive diagnostic agent +[5]

Mechanisms of ActionDiagnostic imaging enhancersReceptor protein-tyrosine kinase erbB-2 binders

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGe Healthcare Laboratory Corporation Of America

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGe Healthcare

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A